F.A. Mistretta

P609 – A phase III prospective randomized trial to evaluate the impact of augmented reality during robot-assisted radical prostatectomy on the rates of postoperative surgical margins: Results after ad interim analysis

S. Luzzago, F.A. Mistretta, M.L. Piccinelli, E. Lievore et autres

PE028 Ad-interim analysis of a phase III prospective randomized trial to evaluate the impact of augmented reality during robot-assisted radical prostatectomy on the rates of postoperative surgical margins

E. Lievore, S. Luzzago, C. Vaccaro, F.A. Mistretta et autres

A phase III prospective randomized trial to evaluate the impact of augmented reality during robot-assisted radical prostatectomy on the rates of postoperative surgical margins

Stefano Luzzago, F.A. Mistretta, Matteo Fontana, M.L. Piccinelli et autres

Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial

Steven Kymes, Neal L. Oden, Paul VanVeldhuisen, Ingrid U. Scott et autres

Importance: Retinal vein occlusion is the second most common retinal vascular disease. Bevacizumab was demonstrated in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to aflibercept with respect to visual acuity in study participants with macular …

us (code pays fourni par la source)

Association between histology and oncological outcomes or complication rates in patients treated with thermal ablation for T1 renal cell tumours

M. Tozzi, F.A. Mistretta, S. Luzzago, M.L. Piccinelli et autres

Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion

Ingrid U. Scott, Neal L. Oden, Paul VanVeldhuisen, Michael S. Ip et autres

Importance: Intravitreal anti-vascular endothelial growth factor (VEGF) injections are commonly used to treat eyes with macular edema secondary to hemiretinal vein occlusion (HRVO) or central retinal vein occlusion (CRVO). Information on whether differences exist in outcomes after anti-VEGF therapy can help guide …

us (code pays fourni par la source)

Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion

Ahmad A. Aref, Ingrid U. Scott, Paul VanVeldhuisen, Jacquie King et autres

IMPORTANCE: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are used to treat a variety of posterior segment conditions, including some associated with glaucoma, such as macular edema due to central retinal vein occlusion (CRVO). Therefore, information regarding intraocular pressure (IOP)-related events associated …

us (code pays fourni par la source)